Samsara BioCapital, LLC - RECURSION PHARMACEUTICALS IN ownership

RECURSION PHARMACEUTICALS IN's ticker is RXRX and the CUSIP is 75629V104. A total of 133 filers reported holding RECURSION PHARMACEUTICALS IN in Q2 2022. The put-call ratio across all filers is 0.76 and the average weighting 2.3%.

Quarter-by-quarter ownership
Samsara BioCapital, LLC ownership history of RECURSION PHARMACEUTICALS IN
ValueSharesWeighting
Q2 2022$2,181,000
-43.5%
267,996
-50.3%
0.58%
-40.2%
Q1 2022$3,861,000
-58.2%
539,2360.0%0.97%
-45.8%
Q4 2021$9,237,000
-46.7%
539,236
-28.4%
1.79%
-34.1%
Q3 2021$17,325,000
-38.8%
752,939
-2.9%
2.72%
-22.2%
Q2 2021$28,309,000775,5833.50%
Other shareholders
RECURSION PHARMACEUTICALS IN shareholders Q2 2022
NameSharesValueWeighting ↓
Kinnevik AB (publ) 10,405,668$77,730,340100.00%
Data Collective IV GP, LLC 5,941,120$44,380,16632.86%
MV Management XI, L.L.C. 1,971,908$14,730,15325.77%
MIC Capital Management UK LLP 8,451,758$63,134,63512.84%
Yong Rong (HK) Asset Management Ltd 1,174,200$8,7723.85%
ArchPoint Investors 1,114,626$8,326,2563.22%
PLATINUM INVESTMENT MANAGEMENT LTD 2,711,148$20,252,2760.70%
HARVARD MANAGEMENT CO INC 882,129$6,5900.65%
Diametric Capital, LP 119,906$895,6980.40%
Lingotto Investment Management LLP 775,077$5,789,8250.37%
View complete list of RECURSION PHARMACEUTICALS IN shareholders